Market Overview

The Simple Case For Being A Chemours Bull

Share:
The Simple Case For Being A Chemours Bull
Related
Regeneron Pharmaceuticals: Sequencing Its Way to +30% Upside
Earnings Scheduled For May 3, 2018

Outlining the investment case for Chemours Co (NYSE: CC), JPMorgan said the company has a proprietary set of very profitable newer generation refrigerants, with patent lives extending to 2022, with excellent growth potential.

Riding On Regulatory Changes

Analysts Jeffrey Zekauskas, Youyou Yan and Silke Kueck noted the new refrigerants are now growing quickly because of demand from the auto OEM market in the U.S. and Europe, driven by regulatory changes to incentivize the use of technology that minimizes global warming.

"We note that the auto after-market is larger than the OEM market, and we expect the technology to make its way into the after-market over time," the analysts said.

Opportunities Galore

JPMorgan noted that the new class of refrigerants is currently being produced only by Chemours and Honeywell International Inc. (NYSE: HON). European and U.S. regulations are also beginning to lead to a movement away from refrigerants for industrial and supermarket use with high global warming potential in favor of low-GWP solutions, the firm added.

The firm sees these are opportunities for Chemours and its Opteon set of products, whose use also tends to lead to reduced power consumption by refrigeration units. According to the firm, the stationary refrigeration markets are multiples of the size of the mobile air conditioning markets.

Multiples Likely To Expand

While noting that Chemours is being valued similarly to Eastman Chemical Company (NYSE: EMN) or Celanese Corporation (NYSE: CE), the firm said there is room for Chemours' multiple to expand because of its longer-term growth opportunities.

"There is also the potential for a rapid adoption of its new products to make a sharp and positive difference to its earnings profile," the firm said.

"Chemours is tripling its Opteon capacity by the end of 2018."

Upgrading Rating

JPMorgan upgraded shares of Chemours to Overweight from Neutral and raised its price target to $50 from $39.

At the time of writing, Chemours shares were rallying 3.15 percent at $43.20.

Related Links:

Biggest Hurdle For Tronox Acquisition Of Cristal? Chinese Regulators

David Einhorn's Letter To Greenlight Investors Reveals New Perrigo Position
___________
Image Credit: Marksie531 at the English language Wikipedia [GFDL (http://www.gnu.org/copyleft/fdl.html) or CC-BY-SA-3.0 (http://creativecommons.org/licenses/by-sa/3.0/)], via Wikimedia Commons

Latest Ratings for CC

DateFirmActionFromTo
May 2018Vertical ResearchInitiates Coverage OnBuy
May 2018CitigroupMaintainsBuyBuy
Apr 2018CitigroupMaintainsBuyBuy

View More Analyst Ratings for CC
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas News Upgrades Price Target Commodities Markets Analyst Ratings Best of Benzinga

 

Related Articles (CE + CC)

View Comments and Join the Discussion!